Post job

Sorrento Therapeutics overview

Industry
Biotechnology
Revenue
Headquarters
Employees
382
Founded in
Website
Organization type
Public
Social media
Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry's most diverse antibody (G-MAB ) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.
Sorrento Therapeutics is a medium health care company with 382 employees and an annual revenue of $62.8M that is headquartered in San Diego, CA.

Sorrento Therapeutics's mission statement

To advance promising new targeted therapies and diagnostics for a vast majority of patients of all ages.

In demand companies are hiring! Let Zippia apply for you!

Floating question marks illustration

3.0/5

Sorrento Therapeutics employee reviews

Based on 1 ratings

Do you work at Sorrento Therapeutics?

Help job seekers learn about working at Sorrento Therapeutics

On this page

Sorrento Therapeutics employee reviews

Sorrento Therapeutics employee reviews
3.0/5

Based on 1 ratings

Work at Sorrento Therapeutics? Share your experience.
Employee reviews
profile
3.0
A zippia user wrote a review on Jan 2020
Pros of working at Sorrento Therapeutics

less heavy job

Cons of working at Sorrento Therapeutics

pay low

Sorrento Therapeutics benefits

they provide free food every friday. They give days off.

Is this useful?
Work at Sorrento Therapeutics? Share your experience

The team at Sorrento Therapeutics

  • The founders of Sorrento Therapeutics are Henry H. Ji and Tony Schuh.
  • The key people at Sorrento Therapeutics are Henry H. Ji and Tony Schuh.
Key people
Henry H. Ji
Tony Schuh

Sorrento Therapeutics salaries

Average Sorrento Therapeutics salary
$75,363
yearly
$36.23 hourly
Updated March 14, 2024

Rate Sorrento Therapeutics' fairness in compensating employees.

Zippia waving zebra

Do you work at Sorrento Therapeutics?

Were you satisfied with Sorrento Therapeutics' salary and benefits?

Sorrento Therapeutics financial performance

9.6
Performance score

We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.

Sorrento Therapeutics currently has 62.8M in revenue. Sorrento Therapeutics's most recent quarter produced 15.0m (q2'2023).

Sorrento Therapeutics annual revenue

$152M
$121M
$91M
$61M
$30M
$0
2017
2018
2019
2020
2021
2022

Are you an executive, HR leader, or brand manager at Sorrento Therapeutics?

Claiming and updating your company profile on Zippia is free and easy.

Sorrento Therapeutics FAQs

Search for jobs

Zippia gives an in-depth look into the details of Sorrento Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Sorrento Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Sorrento Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Sorrento Therapeutics. The data presented on this page does not represent the view of Sorrento Therapeutics and its employees or that of Zippia.

Sorrento Therapeutics may also be known as or be related to SORRENTO THERAPEUTICS INC., Sorrento Therapeutics, Sorrento Therapeutics Inc and Sorrento Therapeutics, Inc.